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Summary The new regimens developed over the last few years have led to an improvement in the treatment of advanced gastric cancer, and
our previous experience confirmed the fact that the combination of etoposide, doxorubicin and cisplatin (EAP regimen) is an active treatment
that leads to interesting complete remission rates. The primary end point of the present multicentre, randomized, parallel-group phase 11 study
was to determine the activity of the simplified 2-day EAP schedule in patients with locally advanced or metastatic gastric cancer, and to verify
whether the addition of low doses of granulocyte-macrophage colony-stimulating factor (GM-CSF) made it possible to increase dose intensity.
Of the 62 enrolled patients, 30 were randomized to receive epirubicin 35 mg m-2, etoposide 120 mg m-2 and cisplatin 45 mg m-2 (FEP) on days
1 and 2 every 28 days and 32 to receive the same schedule plus subcutaneous GM-CSF (molgramostin) 150 ,ug day-1 on days 5-14 every 21
days. The patients were stratified by age and the number of disease sites. The characteristics of the patients were well balanced between the
two groups. The objective response rate of the patients as a whole was 34% (21 out of 62; 95% confidence interval 22-46), with only one
complete remission. The median response duration was 4.5 months (range 1-24 months). The median time to treatment failure was 5 months
(range 1-14 months), without any difference between the two groups. The median survival ofthe patients as a whole was 9 months. Full doses
were administered in 92% and 94% of the cycles in the control and GM-CSF arms respectively. The average dose intensity calculated for all
drugs was 0.96% in the control and 1.27% in the GM-CSF group. CTC-NCI grade 3-4 neutropenia was reported in 39% vs 45% of patients,
thrombocytopenia in 11% vs 35% (P = 0.020) and anaemia in 7% vs 35% (P = 0.014). The FEP combination is as active (OR: 34%) in the
treatment of patients with advanced gastric cancer as the EAP regimen, although it leads to fewer complete remissions. The patients
randomized to receive low-dose GM-CSF achieved a significantly higher dose intensity than controls (P = 0.0001).
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Although the incidence of gastric cancer seems to have declined
regularly in Western countries overthe last decade, it is still one of
the leading causes of death worldwide (Moller et al, 1990).
Furthermore, given that many of the patients are diagnosed when
the disease is unsuitable for curative surgery, there is a pressing
need to develop better systemic therapies in adjuvant, neoadjuvant
and metastatic settings (Macdonald et al, 1992).
The development ofnew chemotherapeutic regimens forthe treat-
ment of advanced gastric cancer, including cisplatin (CDDP), and
anthracycine, or fluorouracil and high-dose methotrexate (EAP,
FAMTX, ECF), has ledtoobjectiveresponses (OR) in 30-40% ofthe
patients, with a complete remission (CR) rate of 10-15% (Wils et al,
1986; Preusser et al, 1989; Findlay et al, 1994; Rougier et al, 1994).
It was initially reported thatthecombination ofetoposide, doxoru-
bicin and CDDP (usually called the EAPregimen) was highly active
in patients with locally advanced and metastatic gastric cancer (64%
of 67 patients responded), but subsequent studies using the same
combination have revealed a much lower response rate associated
with significant haematological toxicity, probably because of the
poor condition ofthe patients (Sparano et al, 1990; Katz et al, 1991).
Received23January 1997
Revised 1 September 1997
Accepted 7October 1997
Correspondence to: E Bajetta, Division of Medical Oncology B, Istituto
Nazionale per lo Studio e la Cura dei Tumor, Via Venezian 1, 20133 Milan, Italy
In our previous multicentre, confirmatory, phase II study
designed to evaluate the efficacy ofthe original EAP combination,
we obtained an OR in 37% (95% CI 27-47%) of 91 treated
patients, with a 12% CR rate (95% CI 5-19%). On the basis ofthis
experience, we consider that the EAP regimen is feasible in an
outpatient setting when administered to patients with an ambula-
tory performance status (Bajetta et al, 1994). However, the length
of the treatment (8 days every 3-4 weeks) proved to be a draw-
back, and so it has been found useful to modify the schedule.
Moreover, many studies have reported the usefulness ofhigh-dose
chemotherapy for many malignancies, but only a few have consid-
ered gastrointestinal cancer (Ajani et al, 1993; Suzuki et al, 1993).
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
is a haematopoietic factor that stimulates the proliferation and
differentiation ofprogenitor cells ofmultiple lineage. A numberof
studies have demonstrated its granulocytosis-stimulating activity
when infused at doses ranging from 125 ,ug m-2 to 500 g m-2, and
the feasibility of low-dose subcutaneous administration has also
been postulated (Steward et al, 1993).
On the basis of these findings, we designed a new regimen
containingCDDP,epirubicin andetoposide (FEP),justifiedbythelack
ofdocumented synergy ofthe drug sequence in the EAPregimen.
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The drugs were administered over 2 days to increase the
synergy between CDDP and etoposide and make the regimen more
feasible in an outpatient setting, in the hope ofobtaining the same
therapeutic results as with the original EAP schedule. The study
was designed as a parallel group phase II trial in which one group
was treated with 3-week cycles of chemotherapy associated with
GM-CSF in an attempt to increase drug dosage; the other was
treated with chemotherapy alone, recycled every 4 weeks.
The primary aim of the study was to determine the efficacy of
the FEP combination in patients with locally advanced or
metastatic gastric cancer; the second aim was to test the feasibility
ofreducing the interval between cycles to 3 weeks by adding low-




The study was conducted by the ITMO (Italian Trials in Medical
Oncology) group, with the reference centre being the Division of
Medical Oncology B of Milan's Istituto Nazionale per lo Studio e
la Cura dei Tumori.
All of the patients had to meet the following inclusion
criteria: age < 68 years; histological confirmation ofgastric adeno-
carcinoma with locally advanced or metastatic disease; ECOG
performance status (PS) < 2; and adequate haematological (WBC
<4000 p-1, granulocytes < 2000 ul-1; and platelets < 120 000pl-1),
renal (serum creatinine gl 1.5 mg% and creatinine clearance
< 60 ml min-1) and hepatic function (bilirubin < 1.5 mg%). The
patients could not be pregnant or have had a previous malignancy,
and they must have been able to give their informed consent. To be
eligible for the study, they had to have lesions that were measur-
able using imaging techniques. Patients with central nervous
system (CNS) metastases were excluded, as were those with
pleural effusions or ascites or peritoneal carcinosis as the only
measurable lesions. The treatment protocol was approved by the
Human Investigation Committee at each of the 16 participating
institutions.
Treatment regimen
The patients were randomized to receive the FEP regimen in
combination with molgramostim (recombinant glycosylated GM-
CSF, Sandoz, Basle, Switzerland) recycled every 21 days, or FEP
alone recycled every 28 days. GM-CSF 150 ,ug day-' was subcuta-
neously injected from day 5 to day 14; if the WBC count was
< 10 000 after 14 days, the injections were continued until day 19
(48 h before the next chemotherapy cycle).
The treatment regimen consisted of an epirubicin 35 mg m-2
intravenous (i.v.) injection, etoposide 120 mg m-2i.v. infusion over
30 min and reconstituted CDDP 45 mg m-2 in a 500-ml saline
solution infused over 30 min on days 1 and 2. The patients also
received 1.000 ml of normal saline with 20 mequiv of potassium
chloride and 8 mequiv of magnesium sulphate before and after
each dose of CDDP. Antiemetic agents were administered
according to the guidelines ofeach institution. Toxicity was graded
using the National Cancer Institute's common toxicity criteria
(CTC-NCI) (Wittes, 1989), and the doses of the drugs were modi-
fied for any toxicity noted on the day of treatment. In the presence
of myelotoxicity CTC-NCI grade 1-4 at recycling (i.e. after
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4 weeks in the arm without, and after 3 weeks in the arm with
GM-CSF), the chemotherapy was delayed by 1 or, if necessary,
2 weeks. If myelotoxicity grade 1-2 persisted after a maximum
delay of 14 days, the dose ofall ofthe drugs was reduced by 25%;
if grade 3 occurred, a 50% reduction was considered; and in
the case of persistent grade 4, the treatment was stopped.
Chemotherapy was not given ifcreatinine clearance was less than
60 ml min-'. The treatment was continued until disease progres-
sion or the appearance oftoxicity, or until the eighth cycle in the
case of a partial response (PR) or stable disease (SD). In the case
of CR, the treatment was continued for a further two cycles and
then stopped.
Assessment
The patients were staged on the basis of the results of a clinical
examination, chest radiograph, abdominal ultrasound or computer-
izedtomography (CT), electrocardiography (ECG), markers (CEA,
CA 19.9) and biochemical screening. The primary tumour was
assessedby means ofendosonography and CT. The clinical exami-
nation and biochemical screen were repeated before each treatment
cycle. Tumour response (as evaluated by imaging studies) and
markers were assessed every two cycles. The standard WHO
response definitions were used (WHO/UICC, 1979). Complete
response required the disappearance of all tumours for a minimum
of 4 weeks; CR of the primary site was defined as a normal
appearing stomach on CT scan, with complete resolution of the
endoscopically visible tumour and anegativebiopsy. PRrequired a
50% decrease in the sum oftheproducts ofall ofthe longest dimen-
sions ofmeasurable lesions for at least 4 weeks; SD was defined as
a less than 50% decrease or a less than 25% increase in lesion size;
and progressive disease (PD) as a less than 25% increase in the size
ofany tumour lesion or the appearance of new sites.
Statistical considerations and analytical plan
In accordance with the Simon's optimal two-stage design, the
study wasplanned to compare a response probability of20% under
the null hypothesis with a response probability of 40% under the
alternative, with an alpha level of 0.05% and a power of 80%
(Simon, 1989). The study had to be stopped and the treatment
judged ineffective in the case that the number of OR (complete or
partial) was three or less in the first 13 patients, or 12 or less in the
total sample of43 subjects. The confidence limits for the response
probability actually observed were computed as described by
Atkinson and Brown (Atkinson et al, 1985).
Blocked randomization was adopted when assigning the treat-
ment regimen (FEP with GM-CSF, or FEP alone), with the strata
defined by age (< 45 or > 45 years) and disease exension (single vs
multiple sites). However, only toxicity was analysed taking the
treatment arm into account: the between-group comparison of the
frequency oftoxic events was made using theMantel-Haenszel test
(Mantel et al, 1959), with the number ofadministered cycles as the
stratification factorand the occurrence ofCTC-NCI grade 3-4 toxi-
city during at least one cycle as the response variable. Such an
approach was suggested by Zucker and Wittes (Zucker et al, 1992)
in order to take into account the possible correlation affecting
repeated within-subject measurements.
Response duration was calculated from the time the response
became evident to the time ofprogression. Survival and the time to
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Table 1 Main patient characteristics
Number of patients
Overall FEP FEP + GM-CSF
Number of randomized patients 62 30 32
Sex: female/male 17/45 9/21 8/24
Age (years): <45/46-68 13/49 5/25 8/24
Median (range) 54(19-71) 59(19-69) 53(33-71)
PS (ECOG scale): 0-1/2 55/7 27/3 28/4
Disease extension
Locally advanced 11 6 5
Local relapse after surgical resection 1 1 -
Metastatic without primary 16 7 9
Metastatic with primary 34 16 18
Number of sites: single/multiple 14/48 6/24 8/24
Disease-free interval
None/< 1 year 45/14 22/6 23/8
> 1 year 3 2 1
treatment failure were assessed from the beginning oftreatment to
the occurrence of the event (death or progression). The survival
function was estimated using the Kaplan-Meier method.
Dose intensity was calculated separately for epirubicin, CDDP
and etoposide, using the planned dose calculated cycle by cycle on
the basis of body weight at the time of that cycle (Bezwoda et al,
1995). Mean dose intensity is expressed in relation to a standard
treatment interval of 28 days as the ratio between the actual and
planned dose multiplied by the ratio between the standard and
actual treatment time. The planned schedule and doses ofintensive
FEP imply a 1.33 relative dose intensity in comparison with
standard FEP.
Table 2 Dose intensity summary statistics
FEP FEP + GM-CSF
Mean number of treatment cycles 3.5 3
Mean treatment time (weeks) 12 9
Dose intensity achieved (mg m-2 week1')
EpiADM 16.90 22.27
Per cent of projected dose 0.96 1.27
VP16 57.93 76.36
Per cent of projected dose 0.96 1.27
CDDP 21.72 28.64
Per cent of projected dose 0.96 1.27
RESULTS
Between September 1993 and December 1995, 62 patients were
randomized to receive the 3-week schedule of chemotherapy with
GM-CSF (n = 32) or the 4-week schedule ofchemotherapy without
GM-CSF (n = 30). Four of the randomized patients received only
one cycle because of treatment-related toxicity (n = 3) or early
discontinuation at the patient's request (n = 1), and three patients
withdrew before receiving any treatment. The characteristics ofthe
62 randomized patients are listed in Table 1. There were no signifi-
cant differences in age, sex, performance status or baseline haema-
tological indices between the two groups. Both groups received the
same median number of cycles, and the median follow-up from
start oftreatment was 7 months (range 1-27 months).
The great majority (89%) of the patients had a good PS, and
82% had metastatic disease. The histological types according to
Lauren's classification were intestinal in 20 patients (32%), diffuse
in 12 (19%), diffuse plus intestinal in two (3%) and undetermined
in 28 (45%). Eleven patients had locally advanced disease before
chemotherapy; eight at surgical exploration; and three after clin-
ical evaluation (CT scan and upper gastrointestinal endoscopy);
however, all ofthese cases had radiologically documented lesions.
It is worth noting that the majority of patients (72%) were
metastatic at diagnosis, and that only three patients had a disease-
free interval of 1 year or more after radical gastrectomy. These
characteristics and the presence of multiple sites in 77% of the
cases meant that the prognosis ofour patients was very poor.
Dose intensity
The median treatment time was three months (range 1-7 months)
for the patients treated with GM-CSF, and four months (range
1-17 months) for those treated without. One hundred cycles were
administered without and 113 with GM-CSF. In the GM-CSF arm,
94% of the cycles were administered at the planned dose; in the
control arm this was 92%. Treatment was postponed for 7 days in
16% and 12% of the cycles with and without GM-CSF respec-
tively; 3% ofthe cycles were delayed by more than 14 days in the
GM-CSF arm, and 9% in the control arm. The median interval
between cycles was 21 days (range 21-49 days) in the GM-CSF
arm, and 28 days (range 21-58 days) in the control arm. The actual
dose intensity achieved is shown in Table 2. The average dose
intensity calculated for all drugs was 0.96% (range 0.48-1) and
1.27% (range 0.94-1.33) in the GM-CSF and control arm respec-
tively, a difference that was statistically significant (P = 0.0001).
Toxicity
The toxicity percentage was calculated in relation to the 59
patients who received at least one cycle; it is worth pointing out
that three of these patients received only one cycle because they
experienced treatment-related toxicity (one in the control arm and
two in the GM-CSF arm, all of whom experienced grade 4
anaemia and thrombocytopenia). The non-haematological and
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Table 3 Non-haematological side-effects
CTC-NCI grade 1 2 3 4
Overall n % n % n % n %
Control patients (28)
Renal toxicity 5 1 4 4 14 - -
Mucositis 8 1 4 6 21 1 4 -
Nausea/vomiting 19 4 14 7 25 8 29
Diarrhoea 4 - 2 7 2 7
Infection 3 - 3 11 -
Neurotoxicity 2 - 1 4 1 4
GM-CSF patients (31)
Renal toxicity 3 1 3 1 3 - 1 3
Mucositis 9 6 19 2 6 1 3 -
Nausea/vomiting 29 11 35 13 42 5 16
Diarrhoea 5 3 10 1 3 - 1 3
Infection 3 2 6 1 3
Neurotoxicity 1 1 3 -
Table 3 Non-haematological side-effects
CTC-NCI grade 1 2 3 4
Overall n % n % n % n %
Control patients (28)
Anaemia 16 7 25 7 25 2 7
Leucopenia 13 1 4 2 7 5 18 5 18
Neutropenia 12 1 4 - 2 7 9 32
Thrombocytopenia 9 2 7 4 14 3 11 -
GM-CSF patients (31)
Anaemia 22 6 19 5 16 7 23 4 13
Leucopenia 18 4 13 4 13 7 23 3 10
Neutropenia 17 3 10 - 5 16 9 29
Thrombocytopenia 16 1 3 4 13 5 16 6 19
haematological toxicities are listed in Tables 3 and 4. There were
no treatment-related deaths. The subcutaneous injection of GM-
CSF was well tolerated by 31 patients, and no evident differences
in non-haematological toxicity were observed between the two
groups, with the exception of a non-significant greater incidence
of grade 2 mucositis in the control group. Grade 3-4 neutropenia
was reported in 39% vs 45% of the patients in the GM-CSF and
control group respectively, thrombocytopenia in 35% vs 11%
(P = 0.020) and anaemia in 35% vs 7% (P = 0.014).
Response
The overall response rate in the intent-to-treat population of 62
patients was 34% (95% CI: 22-46), with only one CR (Table 5).
Moreover, the regimen proved to be active in 42% (95% CI:
27-59) of the first 43 evaluable patients, and in 36% (95% CI
24-55%) of the whole population of 55 evaluable patients. An
objective response rate of 32% was observed in the 50 metastatic
patients. No regression was obtained in the presence of local
relapse after radical surgery.
The responsive disease sites were liver (35%), the primary
tumour (34%) and lymph nodes (30%); these responses were docu-
mented by CT in 12 patients, ultrasound in five and endoscopy in
eight. Both ultrasound and endoscopy were used in four cases, and
endoscopy with CT in eight. The responses were achieved after a
median of2 months (range 1-6 months), and their median duration
was 4.5 months (range 1-24+ months). The median time to treat-
ment failure was five months (range 1-14 months), with an OS in
the randomized patients of9 months (Figure 1).
In eleven patients with locally advanced disease, the overall
response rate was 45% (5 out of 11), with no CR. Two of these
patients underwent second-look laparotomy and the residual
tumour was radically resected; they were still alive after 18+ and
16+ months offollow-up, with a disease-free interval of9 months.
The other three responsive patients did not undergo surgery, and
their survival time was 6, 11 and 15 months.
DISCUSSION
Over the last 10 years, various trials have been conducted in an
attempt to develop more effective combination chemotherapies for
the treatment ofgastric cancer. Although there has been no general
improvement in disease-free oroverall survival, some data indicate
that patients with advanced disease may benefit from treatment
(Glimelius et al, 1994; Kelsen, 1994; Di Bartolomeo et al, 1995;
Pelley, 1995). In particular, patients with locally advanced disease
can expect to receive radical surgery after the regimen, which leads
to a high response rate. Some studies have shown that EAP is a
highly efficacious regimen but has relatively severe bone marrow
toxicity (Preusseretal, 1989; Sparano et al, 1990; Katz etal, 1991).
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Table 5 Response to treatment
Overall FEP FEP + GM-CSF
62 30 32
CR 1 - 1
PR 20 (32%) 12 8
CR + PR 21 (34%) 12 9
SD 6 1 5
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Figure 1 Proportion of surviving patients
Our previous study confirmed that the EAP regimen was active
in inducing objective responses (RR, 37%: CR, 12%), but grade
3-4 myelosuppression was reported in about 30% of the patients
(Bajetta et al, 1994). However, although the study demonstrated
the feasibility of the schedule, side-effects such as myelosuppres-
sion occurred more frequently as the number ofcycles increased or
when the patients were in poor condition, thus meaning that the
treatment had to be delayed or reduced. In an attempt to overcome
this limitation, some trials have used the combination ofhigh-dose
chemotherapy plus growth factors. Ajani et al (1993) documented
that high-dose EAP with GM-CSF is active against gastro-
oesophageal junction adenocarcinoma by obtaining a 50%
response rate. Similar results were achieved by Suzuki et al
(1993), who used high-dose EAP with autologous bone marrow
transplantation, but the high response rate (89%) was not associ-
ated with any benefit in terms of survival; the authors concluded
that the efflcacy of the regimen is limited when the main tumour
has not been resected or in the case ofmetatastic disease.
The present study was designed not to investigate whether an
increase in dose intensity can improve the response rate, but to
evaluate the activity of a simplified schedule in order to overcome
the limitations of the EAP regimen in terms of feasibility. For this
reason, we decided to evaluate its efficacy in the study population
as awhole, given that arandomized study comparing high-dose and
standard-dose chemotherapy is notjustified because ofthe absence
ofa standard regimen for the treatment ofadvanced gastric cancer.
Our results raise two separate points of discussion. First,
although the activity of the FEP and EAP regimens was similar
(OR 34% vs 37%), there was a considerable difference in the CR
rate. Nevertheless, it should be stressed that, unlike the patients
involved in our previous EAP trial, those involved in the present
trial were characterized by poor prognostic factors such as
metastatic disease with primary tumour (70% vs 49%); further-
more, a large number ofcases were metastatic from the beginning
or had multiple disease sites. Nevertheless, the median duration of
survival was similar in the two trials (9 months). Moreover, in the
present study, two cases with locally advanced disease responded
after four cycles and subsequently underwent radical surgery; their
disease-free interval is now 9 months.
Second, this is the first study confirming that the use of low
GM-CSF doses makes it feasible to reduce the interval between
cycles from 4 to 3 weeks, thereby permitting a statistically signifi-
cant increase in dose intensity (0.96% vs 1.27%: P = 0.0001).
However, the use ofGM-CSF cannot be expected to reduce any of
the acute adverse effects ofchemotherapy other than those related
to neutropenia; when it is used to increase the planned dose inten-
sity, as in the present study, there is an increase in the incidence of
other adverse effects, such as thrombocytopenia (P = 0.020) and
anaemia (P = 0.014). These data are confirmed by other experi-
ences (Fischer et al, 1994; Girling et al, 1996; Wall et al, 1995).
In conclusion, although the study demonstrated the effect of
low-dose growth factor on increasing dose intensity, it was not
designed to detect a real clinical benefit. In any case, in the
absence of a front-line therapy for metastatic gastric cancer, it is
very difficult to demonstrate any clinical benefit using increased
dose intensity.
Nevertheless, our results do show that the activity of FEP is
similar to that of other regimens, and it will be interesting to see
the usefulness of this regimen in patients with a limited tumour
burden. In the near future, further studies should be aimed at
testing the effects of a high-dose regimen plus growth factors
when the disease is only microscopic, as is presumed to be the case
after radical surgery.
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